Literature DB >> 31906888

Invasive pseudomembranous upper airway and tracheal Aspergillosis refractory to systemic antifungal therapy and serial surgical debridement in an Immunocompetent patient.

Shihan N Khan1, Rashmi Manur2, John S Brooks2, Michael A Husson2, Kevin Leahy3, Matthew Grant4.   

Abstract

BACKGROUND: The development of respiratory infections secondary to Aspergillus spp. spores found ubiquitously in the ambient environment is uncommon in immunocompetent patients. Previous reports of invasive upper airway aspergillosis in immunocompetent patients have generally demonstrated the efficacy of treatment regimens utilizing antifungal agents in combination with periodic endoscopic debridement, with symptoms typically resolving within months of initiating therapy. CASE
PRESENTATION: A 43-year-old previously healthy female presented with worsening respiratory symptoms after failing to respond to long-term antibiotic treatment of bacterial sinusitis. Biopsy of her nasopharynx and trachea revealed extensive fungal infiltration and Aspergillus fumigatus was isolated on tissue culture. Several months of oral voriconazole monotherapy failed to resolve her symptoms and she underwent mechanical debridement for symptom control. Following transient improvement, her symptoms subsequently returned and failed to fully resolve in spite of increased voriconazole dosing and multiple additional tissue debridements over the course of many years.
CONCLUSIONS: Invasive upper airway aspergillosis is exceedingly uncommon in immunocompetent patients. In the rare instances that such infections do occur, combinatorial voriconazole and endoscopic debridement is typically an efficacious treatment approach. However, some patients may continue to experience refractory symptoms. In such cases, continued aggressive treatment may potentially slow disease progression even if complete disease resolution cannot be achieved.

Entities:  

Keywords:  Antifungal therapy; Endoscopic debridement; Invasive aspergillosis; Refractory disease; Upper airway

Mesh:

Substances:

Year:  2020        PMID: 31906888      PMCID: PMC6945574          DOI: 10.1186/s12879-019-4744-2

Source DB:  PubMed          Journal:  BMC Infect Dis        ISSN: 1471-2334            Impact factor:   3.090


  18 in total

1.  Significance of isolation of Aspergillus from the respiratory tract in diagnosis of invasive pulmonary aspergillosis. Results from a three-year prospective study.

Authors:  V L Yu; R R Muder; A Poorsattar
Journal:  Am J Med       Date:  1986-08       Impact factor: 4.965

2.  Invasive tracheobronchial aspergillosis in an immunocompetent person.

Authors:  Anant Mohan; Randeep Guleria; Seema Mukhopadhyaya; Chinmoyee Das; Anupma Nayak; Surendra Kumar Sharma
Journal:  Am J Med Sci       Date:  2005-02       Impact factor: 2.378

3.  Pseudomembranous Aspergillus tracheobronchitis: a potential for high mortality in low-risk patients.

Authors:  Yuping Li; Fangyou Yu; Chris Parsons; Chengshui Chen; Min Ye; Junru Ye; Yin Zhou; Chang Cai
Journal:  Am J Med Sci       Date:  2013-11       Impact factor: 2.378

4.  Invasive pulmonary aspergillosis in nonimmunocompromised, nonneutropenic hosts.

Authors:  G H Karam; F M Griffin
Journal:  Rev Infect Dis       Date:  1986 May-Jun

5.  Treatment of chronic rhinosinusitis with intranasal amphotericin B: a randomized, placebo-controlled, double-blind pilot trial.

Authors:  Jens U Ponikau; David A Sherris; Amy Weaver; Hirohito Kita
Journal:  J Allergy Clin Immunol       Date:  2005-01       Impact factor: 10.793

Review 6.  Evaluation of the adult with suspected immunodeficiency.

Authors:  Antoine E Azar; Zuhair K Ballas
Journal:  Am J Med       Date:  2007-09       Impact factor: 4.965

7.  Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.

Authors:  Raoul Herbrecht; David W Denning; Thomas F Patterson; John E Bennett; Reginald E Greene; Jörg-W Oestmann; Winfried V Kern; Kieren A Marr; Patricia Ribaud; Olivier Lortholary; Richard Sylvester; Robert H Rubin; John R Wingard; Paul Stark; Christine Durand; Denis Caillot; Eckhard Thiel; Pranatharthi H Chandrasekar; Michael R Hodges; Haran T Schlamm; Peter F Troke; Ben de Pauw
Journal:  N Engl J Med       Date:  2002-08-08       Impact factor: 91.245

8.  Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes.

Authors:  Andres Pascual; Thierry Calandra; Saskia Bolay; Thierry Buclin; Jacques Bille; Oscar Marchetti
Journal:  Clin Infect Dis       Date:  2008-01-15       Impact factor: 9.079

Review 9.  Fungal rhinosinusitis: a categorization and definitional schema addressing current controversies.

Authors:  Arunaloke Chakrabarti; David W Denning; Berrylin J Ferguson; Jens Ponikau; Walter Buzina; Hirohito Kita; Bradley Marple; Naresh Panda; Stephan Vlaminck; Catherine Kauffmann-Lacroix; Ashim Das; Paramjeet Singh; Saad J Taj-Aldeen; A Serda Kantarcioglu; Kumud K Handa; Ashok Gupta; M Thungabathra; Mandya R Shivaprakash; Amanjit Bal; Annette Fothergill; Bishan D Radotra
Journal:  Laryngoscope       Date:  2009-09       Impact factor: 3.325

10.  Invasive tracheobronchial aspergillosis progressing from bronchial to diffuse lung parenchymal lesions.

Authors:  Hiromitsu Ohta; Susumu Yamazaki; You Miura; Minoru Kanazawa; Fumikazu Sakai; Makoto Nagata
Journal:  Respirol Case Rep       Date:  2016-01-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.